Enliven Therapeutics, Inc. (ELVN) has 17 open-market insider trades by 15 insiders since 2011. Over the last six months insiders net sold $52.3M. The most active filer is Orbimed Advisors LLC, 10% Owner.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 10% Owner | — | 2 | $51.7M | 2026-06-22 |
| 5AM Ventures VI, L.P. | 10% Owner | — | 1 | $24.6M | 2024-02-14 |
| Rishi Gupta | Dir10% Owner | — | 1 | $22.9M | 2024-05-16 |
| 5AM Opportunities I (GP), LLC | 10% Owner | — | 1 | $7.5M | 2024-01-31 |
| Andrew J. Schwab | 10% Owner | — | 1 | $7.0M | 2023-08-24 |
| 5AM Opportunities I, L.P. via Kush Parmar | 10% Owner | — | 1 | $3.0M | 2023-09-26 |
| Helen Louise Collins | — | — | 1 | $1.2M | 2026-09-17 |
| J. Scott Garland | Dir | — | 1 | $607K | 2026-10-01 |
| Frederick C. Berndt | CEO10% | — | 2 | $549K | 2012-04-09 |
| Richard A. Heyman | Dir | — | 1 | $348K | 2026-02-17 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| J. Scott Garland | Director | Sell | $607K | 2026-10-01 |
| Benjamin Hohl | CFO | Sell | $303K | 2026-09-17 |
| Helen Louise Collins | — | Sell | $252K | 2026-09-17 |
| Helen Louise Collins | — | Sell | $293K | 2026-08-17 |
| Benjamin Hohl | CFO | Sell | $353K | 2026-08-17 |
| Mika K. Derynck | Director | Sell | $9.6M | 2026-08-04 |
Companies that share insiders with ELVN, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Benjamin Hohl | CFO | Sell | $317K | 2026-07-17 |
| Helen Louise Collins | — | Sell | $263K | 2026-07-17 |
| Lori Anne Kunkel | Director | Sell | $505K | 2026-07-06 |
| Orbimed Advisors LLC | 10% Owner | Sell | $39.0M | 2026-06-22 |
| Helen Louise Collins | — | Sell | $219K | 2026-06-17 |
| Benjamin Hohl | CFO | Sell | $264K | 2026-06-17 |
| Orbimed Advisors LLC | 10% Owner | Sell | $12.7M | 2026-06-15 |
| Lori Anne Kunkel | Director | Sell | $345K | 2026-06-05 |
| Helen Louise Collins | — | Sell | $199K | 2026-05-18 |